98%
921
2 minutes
20
Introduction: Post-infarction left ventricular remodeling is associated with increased mortality in patients with ischemic heart disease. Surgical ventricular reconstruction (SVR) in addition to coronary artery bypass grafting (CABG) has been proposed to reduce left ventricular volume and improve clinical outcomes. The Surgical Treatment for Ischemic Heart Failure (STICH) trial found that the addition of SVR to CABG did not reduce the rates of death or rehospitalization in the 5 years after surgery compared to CABG alone. Like all randomized trials, STICH has limitations and it has been hypothesized that it may have underestimated the treatment effect of SVR. The aim of this study is to evaluate the results of SVR in one of the largest contemporary single-center series and to compare the results with those of the STICH trial using individual patient's data.
Methods And Analysis: Individual data of patients who underwent SVR with or without CABG will be obtained from San Donato University Hospital in Milan. Using multivariable Cox regression analysis, significant prognostic indicators in this cohort will be identified. We will then compare the San Donato cohort to individual patient's data from the SVR arm of Hypothesis 2 of the STICH trial and from both arms of the STICH Extended Study (STICHES). To reduce confounders, propensity score adjustment will be used for this comparison. The primary endpoint will be all-cause mortality. Data will be merged and analyzed independently at Weill Cornell Medicine in New York.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jocs.15315 | DOI Listing |
Medicina (Kaunas)
August 2025
Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
: Heart failure (HF) with reduced ejection fraction (EF) has, in more than 50% of cases, an ischemic etiology and continues to be associated with increased mortality and morbidity despite all the progress registered in the field of medical therapy and interventional revascularization. Myocardial revascularization is extensively used in clinical practice based on the traditional concept that it can improve myocardial function and outcome in ischemic HF. This review is aimed at presenting current knowledge regarding revascularization in patients with chronic ischemic HF and reduced EF.
View Article and Find Full Text PDFDiabetes Care
August 2025
Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
The Diabetes Prevention Program (DPP) was a 3-year randomized clinical trial (RCT) with evaluation of lifestyle and metformin interventions compared with placebo for diabetes prevention in high-risk adults. Both interventions significantly reduced diabetes incidence, prompting the long-term Diabetes Prevention Program Outcomes Study (DPPOS) to assess the progression of diabetes and its complications over 22 years. During follow-up, departures from the original metformin or placebo assignment occurred primarily because of development of diabetes that, by protocol, was managed by clinicians outside the study, after participants developed diabetes with HbA1c ≥7.
View Article and Find Full Text PDFBMJ Support Palliat Care
July 2025
Department of Internal Medicine, University Hospital Cologne Center for Integrated Oncology, Cologne, Germany.
Objectives: Pancreatic and lung cancer are associated with cancer cachexia (CC), which negatively impacts patients' quality of life, treatment outcomes and prognosis. This study aimed to evaluate the feasibility and effectiveness of a 24-week eccentrically overloaded resistance training (ERT) in patients with CC.
Methods: 22 patients with pancreatic or lung cancer and CC were randomised (2:1) to either supervised ERT (n=14) and usual care (UC, n=8).
Am Heart J Plus
June 2025
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States of America.
Introduction: Clinical trials commonly use Cox proportional hazards models, which may be inaccurate when evaluating procedural interventions. Restricted mean survival time (RMST) is an alternative outcome measure that quantifies treatment effects without assuming proportional hazards.
Methods: We determined outcomes based on RMST in the Surgical Treatment for Ischemic Heart Failure (STICH) trial, an international multicenter randomized clinical trial comparing coronary artery bypass grafting (CABG) plus optimal medical therapy to optimal medical therapy alone in patients with ischemic cardiomyopathy.
JACC Heart Fail
May 2025
Yale School of Medicine, New Haven, Connecticut, USA.